Skip to main content
SpringerLink
Log in

Therapeutic Options in Hormone Refractory Prostate Cancer

  • Chapter
Prostate Cancer

  • 128 Accesses

Abstract

Adenocarcinoma of the prostate is the most prevalent tumor in men, a major cause of morbidity and mortality mainly because of the hormone refractory component. Hormone refractory prostate cancer (HRPCA) causes about 42,000 deaths annually [58, 98].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albrecht W, Horenblas S, Marechal JM, Mikisch G, Horwich A, Seretta V, Cassetta G, van Poppel H, Kalman S, Sylvester R (1998) EMP versus EMP/VBL Chemotherapie beim hormonrefraktären Prostatakarzinom. Urologe A 37:32

    Google Scholar 

  2. Benson R, Hartley-Asp B (1990) Mechanisms of action and clinical uses of estramustine. Cancer Invest 8:375

    Article  PubMed  CAS  Google Scholar 

  3. Blumenstein B, Crawford ED, Saiers JH, Stephens RL, Rivkin SE, Coltman CA. Jr (1993) Doxorubicin, mitomycin C and 5-flourouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study. J Urol 150:411–413

    PubMed  CAS  Google Scholar 

  4. Breul J, Paul R (1998) Das Antiandrogen-Entzugssyndrom. Urologe A 37:156–158

    Article  PubMed  CAS  Google Scholar 

  5. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17:3461–3467

    PubMed  CAS  Google Scholar 

  6. Crawford ED, Rosenblum M, Ziada AM, Lange PH. (1999) Overview: hormone refractory prostate cancer. Urology 54 [Suppl 6A]:1–7

    Article  PubMed  CAS  Google Scholar 

  7. Culine S, Kattan J, Zanetta S, Theodore C, Fizazi K, Droz JP. (1998) Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Am J Clin Oncol 21:470–474

    Article  PubMed  CAS  Google Scholar 

  8. DeLa Taille A, Hayek OR, Buttyan R, et al (1999) Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: preliminary investigation on human cell lines and patients. Br J Urol 84: 845–850

    Google Scholar 

  9. DeLa Taille A, Buttyan R, Hayek O, et al (2000) Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 164:1229–1234

    Article  PubMed  Google Scholar 

  10. Denis L (1998) European organization for research and treatment of cancer (EORTC) prostate cancer trials, 1976-1996. Urology 51 [Suppl 5A]:50–57

    Article  PubMed  CAS  Google Scholar 

  11. De Voogt HJ, Sucuiu S, Sylvester R (1989) Univariate analysis of prognostic factors in patients with advanced prostatic carcinoma: results from two European organizations for research on treatment of cancer trials. J Urol 141:883–888

    PubMed  Google Scholar 

  12. Dijkman GA, van Moorseiaar RJ, van Ginckel R, van Stratum P, Wouters L, Debruyne F, Schalken JA, de Coster R (1994) Antitumoral effects of liarozole in in androgen dependent and independent prostate cancer. J Urol 151:217–222

    PubMed  CAS  Google Scholar 

  13. DiPaola RS, Zhang H, Lambert GH, et al (1998) Clinical and biologic activity of an estrogen herbal combination (PC-SPES) in prostate cancer. N Engl J Med 339:785–791

    Article  Google Scholar 

  14. Dowsett M, Shearer RJ, Ponder B.A.J, et al (1988) The effects of aminogluthetimide and hydrocortisone, alone and combined, on androgen levels in prost-orchiectomy prostate cancer patients. Br J Cancer 57:190–192

    Article  PubMed  CAS  Google Scholar 

  15. Dupont A, Gomez JL, Cusan L, Koutselieris M, Labrie F (1993) Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908–913

    PubMed  CAS  Google Scholar 

  16. Ellerhorst JS, Tu SM, Amato RJ. (1997) A phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371

    PubMed  CAS  Google Scholar 

  17. Falcone A, Antonuzzo A, Danesi R, Allegrini G, Monica L, Pfanner E, Masi G, Ricci S, Del Tacca M, Conte P (1999) Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 86:470–476

    Article  PubMed  CAS  Google Scholar 

  18. Figg WD, Sartor O, Cooper MR. (1995) Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98:412–414

    Article  PubMed  CAS  Google Scholar 

  19. Fowler JE, Pandey P, Seaver LE, et al (1995) Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 154:448–453

    Article  PubMed  Google Scholar 

  20. Friedland D, Cohen J, Miller R, Gluckamn R, Zidar B, Lembersky B, Keating M, Voloshin M, Balaban E, Pinkerton R, Reilly N, Dimitt P, Kinney C (1999) A phase II trial in hormone refractory prostate cancer: correlation of antitumor activity to phosphorylation of bcl-2. Proc Am Soc Clin Oncol 18:322a

    Google Scholar 

  21. George DJ, Kanthoff PW. (1999) Prognostic indicators in hormone refractory prostate cancer. Urol Clin North Am 26:303–309

    Article  PubMed  CAS  Google Scholar 

  22. Ghossein RA, Rosai J, Scher HI. (1997) Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 50:100–105

    Article  PubMed  CAS  Google Scholar 

  23. Gomella LG, Ismail M, Nathan FE. (1997) Antiandrogen withdrawal syndrome with nilutamide. J Urol 157:1366

    Article  PubMed  CAS  Google Scholar 

  24. Graefen M, Hammerer P, Haese A, Huland H (2000) Therapieoptionen des hormonrefraktaren Prostatakarzinoms. Urologe A 39:267–273

    Article  PubMed  CAS  Google Scholar 

  25. Haldar S, Basu A, Croce CM. (1996) Bcl-2 is the guardian of the microtubule. Cancer Res 2:389–395

    Google Scholar 

  26. Hartley-Asp B, Kruse E (1986) Nuclear protein matrix as a target for estramustine induced cell death. Prostate 9:387

    Article  PubMed  CAS  Google Scholar 

  27. Herrada J, Dieringer P, Logothetis CJ. (1996) Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol 1996; 155:620–623

    Article  PubMed  CAS  Google Scholar 

  28. Heidenreich A, Engelmann UH, Hofmann R (2001) The use of bisphosphonates for the palliative treatment of painful bone metastases due to hormone refractory prostate cancer. J Urol 165:136–140

    Article  PubMed  CAS  Google Scholar 

  29. Huan SD, Gerridzen RG, Yau JC, et al (1997) Antiandrogen withdrawal syndrome with nilutamide. Urology 49:632–634

    Article  PubMed  CAS  Google Scholar 

  30. Huan SD, Stewart DJ, Aitken SE, Segal R, Yau JC. (1999) Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am J Clin Oncol 22:471–474

    Article  PubMed  CAS  Google Scholar 

  31. Hubert A, Lyass O, Pode D, Gabizon A (2000) Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 11:123–127

    Article  PubMed  CAS  Google Scholar 

  32. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B (1999) Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17:3160–3166

    PubMed  CAS  Google Scholar 

  33. Hudes GR, Nathan F, Khater C (1997) Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone refractory prostate cancer. J Clin Oncol 15:3156

    PubMed  CAS  Google Scholar 

  34. Hussain M, Wolf M, Marshall E, et al (1994) Effects of continued androgen-deprived therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group Report. J Clin Oncol 12:1868–1875

    PubMed  CAS  Google Scholar 

  35. Isaacs JT. (1999) The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 26:263–273

    Article  PubMed  CAS  Google Scholar 

  36. Johnson DE, Babaian RJ, von Eschenbach AC, et al (1988) Ketoconazole therapy for hormonally refractive metastatic prostate cancer. Urology 31:132–134

    Article  PubMed  CAS  Google Scholar 

  37. Joyce R, Fenton MA, Rode P, et al (1998) High dose biclutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159:149–153

    Article  PubMed  CAS  Google Scholar 

  38. Kanthoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506–2513

    Google Scholar 

  39. Kelly WK, Scher H (1993) Prostate specific antigen decline after androgen withdrawal syndrome. J Urol 149:607–613

    PubMed  CAS  Google Scholar 

  40. Kelly WK, Curley T, Leibertz C, et al (1995) Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 13:2208–2213

    PubMed  CAS  Google Scholar 

  41. Kelly WK, Scher HI, Mazumdar M (1995) Suramin and hydrocortisone: determining the efficacy in androgen-independent prostate cancer. J Clin Oncol 13:2214

    PubMed  CAS  Google Scholar 

  42. Klotz L, McNeill I, Fleshner N (1999) A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 161:169–172

    Article  PubMed  CAS  Google Scholar 

  43. Kluog RC, Farah RN, Cerny JC. (1981) Bilateral orchiectomy for carcinoma of the prostate: response of serum testosterone and clinical response to estrogen therapy. Urology 17:49–54

    Article  Google Scholar 

  44. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V (1999) Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33–38

    Article  PubMed  CAS  Google Scholar 

  45. Laurie JA, Hahn RG, Therneau TM. (1992) Chemotherapy for hormonally refractory advanced prostate carcinoma: a comparison of combined versus sequential treatment with mitomycin C, doxorubicin and 5-flou-rouracil. Cancer 69:1440

    Article  PubMed  CAS  Google Scholar 

  46. Logothetis CJ, Samuels ML, von Eschenbach AC. (1983) Doxorubicin, mitomycin C and 5-flourouracil in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1:368

    PubMed  CAS  Google Scholar 

  47. Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hersey D, Gordon R, Rohner T, Drago J, Wettlaufer J, Glode L (1988) Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6:1456–1466

    PubMed  CAS  Google Scholar 

  48. Miglietta L, Canobbio L, Grabetto C, Vannozzi MO, Esposito M, Boccardo F (1997) Suramin/ epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study. J Cancer Res Clin Oncol 123:407–410

    PubMed  CAS  Google Scholar 

  49. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J (1994) Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12:689–694

    PubMed  CAS  Google Scholar 

  50. Murphy GP. (1999) Review of phase II hormone refractory prostate cancer trials. Urology 54 [Suppl 6A]:19–21

    Article  PubMed  CAS  Google Scholar 

  51. Myers CE, Cooper MR, Stein C (1992) Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881

    PubMed  CAS  Google Scholar 

  52. Navone NM, Troncoso P, Pisters LL, et al (1993) P53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657–1663

    Article  PubMed  CAS  Google Scholar 

  53. Newling DW, Dennis L, Vermeylen K (1993) Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer 72:3793–3798

    Article  PubMed  CAS  Google Scholar 

  54. Nieh PT. (1995) Withdrawal phenomenon with the antiandrogen Casodex. J Urol 153:1070–1073

    Article  PubMed  CAS  Google Scholar 

  55. Ornstein DK, Smith DS, Andriole GL. (1998) Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology 52:1094–1097

    Article  PubMed  CAS  Google Scholar 

  56. Osborne CK, Blumenstein BA, Crawford ED, Weiss GR, Bukowski RM, Larrimer NR. (1992) Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group study. Eur J Cancer 28:477–478

    Article  PubMed  CAS  Google Scholar 

  57. Osoba D, Tannock IF, Ernst SD, Neville AJ. (1999) Health related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17:1654–1663

    PubMed  CAS  Google Scholar 

  58. Parker SL, Tong T, Bolden S, Wingo PA. (1996) Cancer statistics, 1997. CA Cancer J Clin 46:5–27

    Article  Google Scholar 

  59. Petrylak DP. (1999) Chemotherapy for advanced hormone refractory prostate cancer. Urology 54 [Suppl 6A] 31–35

    Article  Google Scholar 

  60. Petrylak DP, Macarthur RB, O’Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA. (1999) Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958–967

    PubMed  CAS  Google Scholar 

  61. Pienta KJ, Redman B, Hussain M (1994) Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005–2012

    PubMed  CAS  Google Scholar 

  62. Pienta KJ, Esper PS, Smith DC. (1997) The oral regimen of Cytoxan, prednisone, and diethylbestrol is an active, non-toxic treatment for patients with hormone refractory prostate cancer. Proc Annu Meet Am Soc Clin Oncol 16:1104

    Google Scholar 

  63. Pienta KJ, Redman BG, Bandekar R, Strawderman MA, Cease K, Esper PS, Naik H, Smith DC. (1997) A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50:401–407

    Article  PubMed  CAS  Google Scholar 

  64. Plowman PN, Perry LA, Chard T (1987) Androgen suppression by hydrocortisone without aminogluthetmide in orchiectomised men with prostatic cancer. Br J Urol 59:255–257

    Article  PubMed  CAS  Google Scholar 

  65. Presti JC. (1999) The role of the urologist in adjuvant chemotherapy trials for prostate cancer. Urology 54 [Suppl 6A]:47–50

    Article  PubMed  Google Scholar 

  66. Reese DM, Small EJ. (1999) Secondary hormonal manipulations in hormone refractory prostate cancer. Urol Clin North Am 26:311–319

    Article  PubMed  CAS  Google Scholar 

  67. Richie JP. (1999) Anti-androgens and other hormonal therapies for prostate cancer. Urol Clin North Am 26:15–18

    Article  Google Scholar 

  68. Sartor O, Cooper M, Weinberger M, et al (1994) Surprising activity of flutamide withdrawal, when combined with aminogluthetimide, in treatment of “hormone-refractory” prostate cancer. J Natl Cancer Inst 86:222–227

    Article  PubMed  CAS  Google Scholar 

  69. Schellhammer P, Venner P, Haas G (1997) Prostate specific antigen decreases after withdrawal of antiandrogen therapy with biclutamid or flutamide in patients receiving combined androgen blockade. J Urol 157:1731–1735

    Article  PubMed  CAS  Google Scholar 

  70. Scher H, Steinneck G, Kelly WK. (1995) Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46:142–148

    Article  PubMed  CAS  Google Scholar 

  71. Scher H, Liebertz C, Kelly WK, et al (1997) Biclutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15:2928–2938

    PubMed  CAS  Google Scholar 

  72. Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T (1992) Estramustine and vinblastine: use of prostate specific antigen as a clinical trial and point for hormone refractory prostatic cancer. J Urol 147:931–934

    PubMed  CAS  Google Scholar 

  73. Seidmon EJ, Trump DL, Kreis W, et al (1995) Phase I/II dose-escalation study of liarazole in patients with stage D hormone-refractory carcinoma of the prostate. Ann Surg Oncol 2:550–556

    Article  PubMed  CAS  Google Scholar 

  74. Sella A, Kilbourn R, Amato R (1994) Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12:683

    PubMed  CAS  Google Scholar 

  75. Sinibaldi VJ, Carduci MA, Moore-Cooper S, Enger C, Laufer M, Wolff C, Eisenberger MA. (1999) A phase II study evaluating a one day course of estramustine phosphate and docetaxel in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 18:322a

    Google Scholar 

  76. Small EJ, Carroll PR. (1994) Prostate specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43:408–410

    Article  PubMed  CAS  Google Scholar 

  77. Small EJ, Srinivas S (1995) The antiandrogen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76:1428–1434

    Article  PubMed  CAS  Google Scholar 

  78. Small EJ, Srinivas S, Egan B, McMillan A, Rearden TP. (1996) Doxorubicin and dose-escalating cyclophophamide with granulocyte colony-stimulating factor for the treatment of hormoneresistant prostate cancer. J Clin Oncol 14:1617–1625

    PubMed  CAS  Google Scholar 

  79. Small EJ, Baron AD, Fippin L, et al (1997) Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157:1204–1207

    Article  PubMed  CAS  Google Scholar 

  80. Small EJ, Baron AD, Bok R, et al (1997) Simultaneous anitandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 80:1755–1759

    Article  PubMed  CAS  Google Scholar 

  81. Small EJ, Frohlich MW, Bok R, et al (2000) Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595–3603

    PubMed  CAS  Google Scholar 

  82. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichemeyer WJ, Eisenberger M (2000) Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18:1440–1450

    PubMed  CAS  Google Scholar 

  83. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. (1998) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16:1835–1843

    PubMed  CAS  Google Scholar 

  84. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. (1998) A phase II trial of oral diethylbestrol as a second line hormonal agent in advanced prostate cancer. Urology 52:257–260

    Article  PubMed  CAS  Google Scholar 

  85. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. (1999) Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664–1671

    PubMed  CAS  Google Scholar 

  86. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G (1997) Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79:933–941

    Article  PubMed  CAS  Google Scholar 

  87. Tannock IF, Gospodarowicz M, Meakin W, et al (1989) Treatment of metastatic prostate cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590–597

    PubMed  CAS  Google Scholar 

  88. Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin C.M.L, Murphy KC. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764

    PubMed  CAS  Google Scholar 

  89. Taplin ME, Bubley GJ, Shuster TD, et al (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393–1398

    Article  PubMed  CAS  Google Scholar 

  90. Taylor CD, Elson P, Trump DL. (1993) Importance of continued testicular suppression in hormone refractory prostate cancer. J Clin Oncol 11:2167–2172

    PubMed  CAS  Google Scholar 

  91. Tew KD, Stearns ME. (1987) Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. Urol Res 15:155

    Article  PubMed  CAS  Google Scholar 

  92. Tilley WD, Buchanan G, Hickey TE, et al (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277–285

    PubMed  CAS  Google Scholar 

  93. Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P (1994) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73:1478–1484

    Article  PubMed  CAS  Google Scholar 

  94. Veronesi A, Re GL, Foladore S, Merlo A, Giuliotto N, Talamini R, Monfradini S (1996) Multidrug chemotherapy in the treatment of non-elderly patients with hormone-refractory prostatic carcinoma. A phase II study. North Eastern Italian Oncology Group. Eur Urol 29:434–438

    PubMed  CAS  Google Scholar 

  95. Visakorpi T, Hyytinen E, Kovisto P, et al (1995) In vivo amplification of the androgen receptor and progression of prostate cancer. Nat Genet 9:401–409

    Article  PubMed  CAS  Google Scholar 

  96. Vogelzang NJ, Crawford ED, Zietman A (1998) Current clinical trial design issues in hormonerefractory prostate cancer. Cancer 82:2093–2101

    Article  PubMed  CAS  Google Scholar 

  97. Weitzman A, Shelton G, Zuech N, Englnad-Owen C, Newhouse J, Bagiella E, Katz A, Sawczuk I, Benson M, Olsson C, Petrylak DP. (1999) Phase II study of estramustine combined with docetaxel in patients with androgen-independent prostate cancer. Proc Am Soc Clin Oncol 18:355a

    Google Scholar 

  98. Wingo PA, Landis S, Ries L.A.G. (1997) An adjustment to the 1997 estimate for new prostate cancer. CA Cancer J Clin 47:239–242

    Article  PubMed  CAS  Google Scholar 

  99. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 1098–1109

    Google Scholar 

Download references

Authors
  1. A. Heidenreich
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology and Pediatric Urology, Philipps Universität Marburg, Baldingerstrasse 3, 35043, Marburg/Lahn, Germany

    Reiner Hofmann  & Axel Heidenreich  & 

  2. Department of Surgery, USUHS, 430 I Jones Bridge Road, 20814-4799, Bethesda, MD, USA

    Judd W. Moul M.D. (Professor of Urology) (Professor of Urology)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Heidenreich, A. (2003). Therapeutic Options in Hormone Refractory Prostate Cancer. In: Hofmann, R., Heidenreich, A., Moul, J.W. (eds) Prostate Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56321-8_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56321-8_27

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62643-2

  • Online ISBN: 978-3-642-56321-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation